Patents Examined by Christina Bradley
-
Patent number: 11964003Abstract: The present invention relates to the use of aprotic polar solvents and an ionization stabilizing agent to prepare storage stable sustained release therapeutic formulations by dissolving a therapeutic agent (active ingredient) in an aprotic polar solvent system that can then be administered to patients suffering from or predisposed to a variety of physical conditions or disorders, notably hypoglycemia.Type: GrantFiled: June 25, 2021Date of Patent: April 23, 2024Assignee: XERIS PHARMACEUTICALS, INC.Inventors: Evan Cassavaugh, Steven Prestrelski
-
Patent number: 11957736Abstract: The present invention concerns the use of aprotic polar solvents, water, and an ionization stabilizing agent to prepare device compatible stable therapeutic formulations by dissolving a therapeutic agent (active ingredient) in an aprotic polar solvent system that can then be used with various devices (e.g., pumps, infusion sets) for administration of the formulation. In certain embodiments, the invention is directed to formulations comprising one or more therapeutic agents, as well as methods of making such formulations, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system, such as a DMSO/water admixture, comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.Type: GrantFiled: February 13, 2023Date of Patent: April 16, 2024Assignee: Xeris Pharmaceuticals, inc.Inventors: Martin Donovan, Wendy Hu
-
Patent number: 11952434Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.Type: GrantFiled: April 20, 2022Date of Patent: April 9, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell
-
Patent number: 11931397Abstract: The disclosure provides methods of preventing or treating Sengers syndrome in a mammalian subject, reducing risk factors associated with Sengers syndrome, and/or reducing the likelihood or severity of Sengers syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of AGK in subjects in need thereof.Type: GrantFiled: December 5, 2019Date of Patent: March 19, 2024Assignee: STEALTH BIOTHERAPEUTICS INC.Inventors: James Carr, Michael Dimatteo, Anthony Abbruscato, Hans Bjornsson
-
Patent number: 11903994Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.Type: GrantFiled: October 7, 2016Date of Patent: February 20, 2024Assignee: Apellis Pharmaceuticals, Inc.Inventors: Federico Grossi, Pascal Deschatelets, Cedric Francois
-
Patent number: 11890328Abstract: A protein composition derived from silk fibroin, which composition possesses enhanced solubility and stability in aqueous solutions. The primary amino acid sequence of native fibroin is modified in the SDP such that cysteine disulfide bonds between the fibroin heavy and fibroin light protein chains are reduced or eliminated. Additionally, the composition can have a serine content that is reduced by greater than 40% compared to native fibroin protein, and the average molecular weight of the SDP is less than about 100 kDa.Type: GrantFiled: June 28, 2021Date of Patent: February 6, 2024Assignee: Silk Technologies, Ltd.Inventors: Brian D. Lawrence, David W. Infanger
-
Patent number: 11891455Abstract: This intention relates to a novel polymorph form of compound (R)-2-[2-amino-3-(indol-3-yl)propionylamino]-2-methylpropionic acid, a process for making the novel polymorph form of the compound, and uses thereof for making other polymorph forms of the compound. The invention further relates to composition comprising novel polymorph form of the compound and a pharmaceutically acceptable carrier or excipient.Type: GrantFiled: September 23, 2020Date of Patent: February 6, 2024Inventors: Jozsef Repasi, Andras Szabo, Markus Henrich
-
Patent number: 11890315Abstract: The application is directed a composition comprising organic acid (e.g., ascorbic acid), glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically-acceptable salt thereof, or any combination thereof, and methods of using the same. In certain aspects the application is directed to glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically-acceptable salt thereof; and an organic acid; wherein the molar ratio is about 0.5-1:1. The composition can further comprises a bicarbonate salt, wherein the molar ratio is about 0.1-0.5:0.5-1:1.Type: GrantFiled: October 7, 2022Date of Patent: February 6, 2024Assignee: RENOVION, INC.Inventors: Dan Copeland, Carolyn Durham
-
Patent number: 11883461Abstract: The present invention is related to the use of HMGB1 antagonists such as K883 in the treatment and/or prevention and/or inhibition of severe sepsis in mammals, e.g., humans, and pharmaceutical compositions for the same comprising HMGB1 antagonists in an effective amount to treat and/or prevent and/or inhibit this condition.Type: GrantFiled: August 30, 2022Date of Patent: January 30, 2024Assignee: THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCHInventor: Yousef Al-Abed
-
Patent number: 11884708Abstract: The invention concerns stapled peptide inhibitors of NEMO which inhibit the Nuclear Factor ?B (NF-?B) signaling pathway and are useful as medicine candidates, in particular as anti-inflammatory or anticancer drugs.Type: GrantFiled: September 28, 2021Date of Patent: January 30, 2024Assignee: INSTITUT PASTEURInventors: Fabrice Agou, Alix Boucharlat, Yves-Marie Coic, Françoise Baleux
-
Patent number: 11879019Abstract: An enzyme-responsive peptide and a method off using such enzyme-responsive peptide are disclosed. An enzyme-responsive peptide, the peptide comprising an amino acid having an ?-amino group, an ?-carboxylic acid group and a ?-amine group, wherein the ?-amine group is covalently bonded with a first group and the ?-carboxylic acid is covalently bonded with a second group.Type: GrantFiled: December 19, 2017Date of Patent: January 23, 2024Assignee: The Regents of the University of CaliforniaInventors: Heather D. Maynard, Natalie Boehnke
-
Patent number: 11857603Abstract: The present invention relates to a pharmaceutical composition comprising a PTH compound, wherein after subcutaneous administration the pharmacokinetic profile of the PTH compound exhibits a peak to trough ratio of less than 4 within one injection interval.Type: GrantFiled: November 8, 2022Date of Patent: January 2, 2024Assignee: ASCENDIS PHARMA BONE DISEASES A/SInventors: Kennett Sprogøe, Lars Holten-Andersen, David Brian Karpf, Felix Cleemann, Guillaume Maitro, Mathias Krusch, Thomas Wegge, Joachim Zettler
-
Patent number: 11845809Abstract: The present invention relates to a salt of a compound of formula (I) and uses thereof in medicine. Specifically, it relates to maleate of compound of formula (I) and pharmaceutically compositions thereof. Furthermore, the invention relates to the uses of maleate herein and pharmaceutically compositions thereof disclosed herein in the manufacture of a medicament, especially in the manufacture of a medicament for preventing, managing, treating or lessening hepatitis C virus (HCV) infection.Type: GrantFiled: December 14, 2018Date of Patent: December 19, 2023Assignee: WATERSTONE PHARMACEUTICALS(WUHAN) CO., LTD.Inventors: Jian Cui, Yao Yu, Minglong Hu
-
Patent number: 11813312Abstract: The present invention relates to the medical use of specific long-acting glucagon analogues having dual GLP-1/glucagon receptor agonist activity in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), NAFLD-associated liver fibrosis and/or cirrhosis.Type: GrantFiled: April 22, 2021Date of Patent: November 14, 2023Assignee: Boehringer Ingelheim International GmbHInventor: Leo Thomas
-
Patent number: 11773147Abstract: The present disclosure provides human tear lipocalin muteins that specifically bind to LAG-3, which can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure further shows the human lipocalin muteins can inhibit the binding of LAG-3 to MHC class II on cells overexpressing MHC class II. The present disclosure also concerns methods of making LAG-3 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.Type: GrantFiled: October 12, 2021Date of Patent: October 3, 2023Assignee: Pieris Pharmaceuticals GmbHInventors: Christine Rothe, Shane Olwill, Andrea Allersdorfer, Timo Eichner, Rachida Siham Bel Aiba, Marina Pavlidou
-
Patent number: 11767353Abstract: Fusion polypeptides with modified multimerization domains that provide high expression, solubility, stability, and low immunogenicity to the fusion polypeptides have been developed. TRAIL compositions with the modified multimerization domains show improved physico-chemical and biological properties relative to TRAIL compositions with unmodified multimerization domains. The TRAIL compositions also have lower immunogenicity in the mammalian host when compared to that of TRAIL compositions with unmodified multimerization domains. The TRAIL compositions induce apoptosis of cancer cells and cancer-associated fibroblasts in vivo, reducing tumor size.Type: GrantFiled: April 6, 2021Date of Patent: September 26, 2023Assignee: THERALY FIBROSIS, INC.Inventors: Alex Sokoloff, Viktor Roschke, Kang Choon Lee, Seulki Lee, Yumin Oh
-
Patent number: 11759504Abstract: The present invention relates to a pharmaceutical composition comprising a PTH compound, wherein after subcutaneous administration the pharmacokinetic profile of the PTH compound exhibits a peak to trough ratio of less than 4 within one injection interval.Type: GrantFiled: September 28, 2017Date of Patent: September 19, 2023Assignee: Ascendis Pharma Bone Diseases A/SInventors: Kennett Sprogøe, Lars Holten-Andersen, David Brian Karpf, Felix Cleemann, Guillaume Maitro, Mathias Krusch, Thomas Wegge, Joachim Zettler
-
Patent number: 11760779Abstract: The preparation of water dispersible ceramide conjugates and derivatives of sphingolipid analogues is described. The conjugates and analogues are prepared by reacting a succinimidyl carbonate of a ?-Ala derivative with the primary amine of a functionalised spacer. Despite their dispersibility in water, the ceramide conjugates and derivatives of sphingolipid analogues spontaneously incorporate into the plasma membranes of cells.Type: GrantFiled: June 4, 2018Date of Patent: September 19, 2023Assignee: KODE BIOTECH LIMITEDInventors: Nicolai Vladimirovich Bovin, Stephen Micheal Henry, Alexander Borisovich Tuzikov
-
Patent number: 11759509Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.Type: GrantFiled: October 17, 2018Date of Patent: September 19, 2023Assignees: Sumitomo Pharma Co., Ltd., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.Inventors: Chiang Jia Li, Hitoshi Ban, Yukihiro Nishio, Masashi Goto, Toshio Nishihara, Yosuke Takanashi
-
Patent number: 11739134Abstract: This invention relates to isolated polypeptides that are long acting analogs of human PYY. The disclosed PYY analog polypeptides have beneficial physicochemical properties relative to endogenous PYY and known synthetic PYY analog polypeptides, such as longer (i.e., “long-acting”) elimination half-lives (t1/2), and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed PYY analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed PYY analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as type 2 diabetes, treating obesity, and providing weight loss, and in methods of treating nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).Type: GrantFiled: April 16, 2021Date of Patent: August 29, 2023Assignee: Intarcia Therapeutics, Inc.Inventors: William Blackwell, Ved P. Srivastava, James M. Way